FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Who is this study for? Patients with Liver Metastasis Colon Cancer
What treatments are being studied? FOLFOXIRI
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• ECOG perfomance 0-1
• pathologically confirmed colorectal carcinoma, with RAS wild type
• inital unresectable liver metastases discussed by MDT
• prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery.
• without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)
• adequate blood, liver and renal function
• expected survival longer than 6 months
Locations
Other Locations
China
Department of Colorectal Surgery Fudan University Shanghai Cancer Center
RECRUITING
Shanghai
Contact Information
Primary
Wenhua Li
whliiris@hotmail.com
13817922257
Time Frame
Start Date: 2021-04-17
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 160
Treatments
Experimental: FOLFOXIRI+C225
Active_comparator: FOLFOXIRI+BEV
Related Therapeutic Areas
Sponsors
Leads: Fudan University